Aardvark Therapeutics Stock Forecast
NASDAQ: AARDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:02 AM ET
AARD analyst consensus
Consensus (12 analysts)
buy
Avg. price target
$11.11+134.39%
- Strong buy 0
- Buy 6
- Hold 4
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Aardvark Therapeutics (2026-10-09), 6 rate the stock a buy or strong buy, 4 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $11.11, with a high estimate of $28.00 and a low estimate of $3.00. The average target implies upside of 134.4% from the current price of $4.74.
The spread between the highest and lowest targets is 833.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AARD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 6 | 50% |
| Hold | 4 | 33% |
| Sell | 1 | 8% |
| Strong sell | 1 | 8% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $3.00 | -36.71% |
| Average target | $11.11 | +134.39% |
| High target | $28.00 | +490.72% |